Re­struc­tured Melin­ta now wants to buy fel­low an­tibi­ot­ic mak­er Tetraphase; TA As­so­ciates mulls $500M deal for a stake in CD­MO

→ Yet an­oth­er buy­er has emerged in what is shap­ing up to be a bid­ding war for Tetraphase and its mar­ket­ed an­tibi­ot­ic. Melin­ta — a fel­low an­tibi­otics mak­er that’s fresh­ly re­struc­tured un­der Chap­ter 11 and now pri­vate­ly owned by Deer­field — is of­fer­ing to buy it all for $27 mil­lion, more than dou­ble the orig­i­nal of­fer by Acel­Rx that the Tetraphase board had rec­om­mend­ed back in March. Since then, La Jol­la has al­so pro­posed a $22 mil­lion deal.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN